Study Estimating the Impact of Prevnar 13™ (13vPnC) on Invasive Pneumococcal Disease
| Status: | Completed |
|---|---|
| Conditions: | Pneumonia, Infectious Disease |
| Therapuetic Areas: | Immunology / Infectious Diseases, Pulmonary / Respiratory Diseases |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 12/6/2018 |
| Start Date: | July 2010 |
| End Date: | April 2015 |
A Postmarketing Observational Study Estimating The Impact Of Prevnar 13 (Trade Mark) (13vpnc) On Invasive Pneumococcal Disease Caused By Vaccine Serotypes Of Streptococcus Pneumoniae After Introduction Into Routine Pediatric Use
This study will estimate the incidence of invasive pneumococcal disease in members of the
Northern Kaiser Permanente healthcare system during each of the 5 following introduction of
Prevnar 13.
Northern Kaiser Permanente healthcare system during each of the 5 following introduction of
Prevnar 13.
No sampling as no subjects are enrolled
Inclusion Criteria:
- Documented invasive pneumococcal disease (IPD), defined as recovery of an isolate of S
pneumoniae from a normally sterile site in a member of the surveillance population.
Exclusion Criteria:
We found this trial at
1
site
Click here to add this to my saved trials
